title: Abruptio placentae associated with misoprostol use in women with preeclampsia.
abstract: OBJECTIVE
  To evaluate complications associated with cervical ripening with vaginal administration of misoprostol and dinoprostone vaginal inserts in women with preeclampsia. preeclampsia.
  
  
  METHODS
  Retrospective study of patients with preeclampsia undergoing cervical ripening with vaginal misoprostol and dinoprostone vaginal inserts prior to labor induction.
  
  
  RESULTS
  Among 203 patients with preeclampsia undergoing cervical ripening prior to induction, 95 received vaginal misoprostol, and 108 received dinoprostone. The incidence of uterine hyperstimulation requiring medical therapy and the need for emergency cesarean section due tofetal heart rate abnormalities were significantly higher among patients receiving misoprostol (22.1% versus 12.0%, p = 0.04, and 17.9% versus 8.3%, p = 0.03, respectively). The overall incidence of abruptio placentae was 7.4%, with a significantly higher incidence among those receiving misoprostol as compared to dinoprostone (13.7% versus 1.9%, p = 0.001).
  
  
  CONCLUSIONS
  Among patients with preeclampsia undergoing cervical ripening prior to labor induction, there is a higher incidence of acute intrapartum complications (uterine hyperstimulation, cesarean section for fetal heart rate abnormalities and abruptio placentae) with vaginal misoprostol, as compared to dinoprostone, vaginal insert.
authors.affiliation: Florida Perinatal Associates, Tampa, USA. tffpa@aol.com
authors.forename: M Todd
authors.initials: MT
authors.lastname: Fontenot
authors.forename: David F
authors.initials: DF
authors.lastname: Lewis
authors.forename: C Brent
authors.initials: CB
authors.lastname: Barton
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Jones
authors.forename: Jodi A
authors.initials: JA
authors.lastname: Moore
authors.forename: Arthur T
authors.initials: AT
authors.lastname: Evans
mesh_terms: D000037:Abruptio Placentae / Q000209:etiology*; D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D001034:Apgar Score; D020070:Cervical Ripening / Q000187:drug effects*; D002585:Cesarean Section; D036861:Delivery, Obstetric; D015232:Dinoprostone / Q000009:adverse effects*; D005260:Female; D006340:Heart Rate, Fetal / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced; D016595:Misoprostol / Q000009:adverse effects*; D009846:Oliguria / Q000209:etiology; D010120:Oxytocics / Q000009:adverse effects*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011654:Pulmonary Edema / Q000209:etiology; D012189:Retrospective Studies
chemical_list: D010120:Oxytocics; D016595:Misoprostol; D015232:Dinoprostone